Kane Biotech Inc. (CVE:KNE – Get Free Report) Director Philip Renaud sold 2,000,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of C$0.13, for a total transaction of C$260,000.00.
Kane Biotech Stock Performance
Kane Biotech stock opened at C$0.13 on Wednesday. The company has a quick ratio of 0.39, a current ratio of 0.37 and a debt-to-equity ratio of 1,164.24. Kane Biotech Inc. has a twelve month low of C$0.05 and a twelve month high of C$0.17. The company’s 50-day moving average price is C$0.11 and its 200-day moving average price is C$0.09. The company has a market cap of C$17.14 million, a PE ratio of -4.33 and a beta of 0.56.
Kane Biotech (CVE:KNE – Get Free Report) last issued its quarterly earnings data on Tuesday, March 26th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.04 million during the quarter.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name.
See Also
- Five stocks we like better than Kane Biotech
- What to Know About Investing in Penny Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What is a Secondary Public Offering? What Investors Need to Know
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
